



Patient Name: _____

Date of Birth: _____

PHYO
CMC85949-001NS Rev. 9/2021**Tocilizumab (ACTEMRA)
Infusion Therapy Plan****Baseline Patient Demographic**

To be completed by the ordering provider.

Diagnosis: _____ Height: _____ cm Weight: _____ kg Body Surface Area: _____ (m²) NKDA - No Known Drug Allergies Allergies: _____**Therapy Plan orders extend over time (several visits) including recurring treatment.**

Please specify the following regarding the entire course of therapy:

Duration of treatment: _____ weeks _____ months _____ unknown

Treatment should begin: as soon as possible (within a week) within the month****Plans must be reviewed / re-ordered at least annually. ******ORDERS TO BE COMPLETED FOR EACH THERAPY****ADMIT ORDERS** **Height and weight** **Vital signs**

Starting when released, temperature, respiratory rate, pulse, blood pressure (BP), O2 saturation

HYPOTENSION DEFINED ADMIT **Nursing communication**

Prior to starting infusion, please determine the patient's threshold for hypotension as defined by the following parameters. This information will be needed in the event of an infusion reaction.

Hypotension is defined as follows:

1 month to 1 year - systolic blood pressure (SBP) less than 70

1 year to 11 years - systolic blood pressure (SBP) less than 70 + (2 x age in years)

11 years to 17 years - systolic blood pressure (SBP) less than 90

OR any age - systolic blood pressure (SBP) drop of more than 30% from baseline.

Baseline systolic blood pressure (SBP) x 0.7 = value below defined as hypotension.

 Nursing communication

Assess patient for signs of illness and previous infusion reactions.

PREGNANCY TESTS AT DALLAS AND PLANO**Nursing communication**

Only one pregnancy test is necessary, based on facility capabilities. Please utilize the lab that is available per facility.

 Patient requires a pregnancy test (based on organizational policy, female patients 10 years of age or over require a pregnancy test)**Pregnancy test, urine - POC**STAT, ONE TIME, for females \geq 10 years old. If positive, do NOT infuse and contact the ordering provider.**Gonadotropin chorionic (HCG) urine**STAT, ONE TIME, unit collect, for females \geq 10 years old. If positive, do NOT infuse and contact ordering provider.**Gonadotropin chorionic (HCG) urine**STAT, ONE TIME, unit collect, for females \geq 10 years old. If positive, do NOT infuse and contact ordering provider.**NURSING ORDERS**

Please select all appropriate therapy

 IV START NURSING ORDERS**Insert Peripheral IV**

Place PIV if needed or access IVAD if available.



Patient Name: _____

Date of Birth: _____

 PHYO
 CMC85949-001NS Rev. 9/2021

**Tocilizumab (ACTEMRA)
 Infusion Therapy Plan**
ORDERS TO BE COMPLETED FOR EACH THERAPY
NURSING ORDERS, CONTINUED
 lidocaine 1% BUFFERED (J-TIP LIDOCAINE)

0.2 mL, INTRADERMAL, PRN

 when immediate procedure needed
 when procedure will take about 1 minute
 patient / family preference for procedure

 Administration Instructions: NOTE: Do not use this medication in patients with bleeding disorders, platelets \leq 20,000, or in patients taking anticoagulants, when accessing implanted ports or using a vein that will be utilized for chemotherapy administration, nor for pre-term infants or neonates.

 lidocaine - prilocaine (EMLA) cream

TOPICAL, PRN

 when more than 60 minutes are available before procedure
 when procedure will take more than 1 hour

 patient / family preference for procedure

Administration Instructions: NOTE: In children < 3 months of age, or < 5 kg in weight, maximum application time is 1 hour.

 lidocaine - tetracaine (SYNERA) patch

TOPICAL, PRN

 when 20 - 30 minutes are available before procedure
 when procedure will take more than 1 hour

 when anticipated pain is less than 5 mm from skin surface
 patient / family preference for procedure

 lidocaine with transparent dressing 4% kit

TOPICAL, PRN

 when 20 - 30 minutes are available before procedure
 when procedure will take more than 1 hour

 patient / family preference for procedure

 Heparin flush
heparin flush

10 - 50 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. This heparin flush should be used with all central lines including IVADs, with the exception of de-accessing the IVAD.

heparin flush

100 - 300 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. For use only when de-accessing IVADs.

 Sodium chloride flush
Sodium chloride flush 0.9% injection

1 - 20 mL, INTRAVENOUS, PRN, IV line flush

Sodium chloride - preservative free 0.9% injection

1 - 30 mL, INTRAVENOUS, PRN, IV line flush

PRE-MEDICATIONS
 Acetaminophen pre-medication 30 minutes prior (15 mg / kg, maximum 650 mg)
Nursing communication

Administer only one of the acetaminophen orders, suspension or tablets, do not give both.

acetaminophen suspension

15 mg / kg, ORAL, for 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____

acetaminophen tablet

15 mg / kg ORAL, for 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____



Patient Name: _____

Date of Birth: _____

 PHYO
 CMC85949-001NS Rev. 9/2021

**Tocilizumab (ACTEMRA)
 Infusion Therapy Plan**
ORDERS TO BE COMPLETED FOR EACH THERAPY
PRE-MEDICATIONS, CONTINUED

-
- Diphenhydramine pre-medication 30 minutes prior (1 mg / kg, maximum 50 mg)**

Nursing communication

Administer only one of the diphenhydrAMINE pre-medication orders, liquid, capsule or injection, do not give more than one of the orders as a pre-medication.

diphenhydrAMINE liquid

1 mg / kg, ORAL, for 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____

diphenhydrAMINE capsule

1 mg / kg ORAL, for 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____

diphenhydrAMINE injection

1 mg / kg, INTRAVENOUS, 1 dose pre-medication, give 30 minutes prior to infusion

Dose: _____

INTRA-PROCEDURE

-
- Physician communication order**

Please select 'Tocilizumab every 2 weeks for systemic JIA' section or 'Tocilizumab every 4 weeks for polyarticular JIA' section and the appropriate labs and dosing are contained in each section depending on diagnosis.

-
- Therapy Appointment Request**

Please select department for the therapy appointment request:

Expires in 365 days

 Dallas Special Procedures
 Plano Infusion Center
 Dallas Allergy
 Dallas Transplant
 Dallas Neurology

Tocilizumab for Systemic JIA or Polyarticular JIA (Select one):

-
- Tocilizumab Every 2 Weeks for Systemic JIA**

-
- Physician communication order**

CBC and liver panel prior to 2nd, 3rd, and 4th infusion, then every other month. Lipid panel 3rd infusion, then every 6 months.

-
- Complete Blood Count With Differential**

Unit collect

Prior to 2nd, 3rd, and 4th infusion, then every other month.

INTERVAL: Every 2 weeks **DEFER UNTIL:** _____ **DURATION:** 3 treatments

-
- Complete Blood Count With Differential**

Unit collect

Every other month.

INTERVAL: Every 8 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

-
- Hepatic Function Panel**

Unit collect

Prior to 2nd, 3rd, and 4th infusion then every other month

INTERVAL: Every 2 weeks **DEFER UNTIL:** _____ **DURATION:** 3 treatments

-
- Hepatic Function Panel**

Unit collect

Every other month.

INTERVAL: Every 8 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

-
- Lipid Panel**

Unit collect

Prior to 3rd infusion, then every 6 months.

INTERVAL: Every 24 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

-
- Nursing communication**

 Parameters to meet prior to administration: WBC \geq 4 thousand / mm³ or ANC \geq 1,500. Notify ordering provider if aparameters are not met.

-
- Vital signs**

 Monitor respiratory rate, pulse and blood pressure (BP) every 15 minutes during infusion and for a total of 30 minutes after patient completes infusion. If patient develops fever, chills, pruitus, urticaria, chest pain, shortness of breath, low or high blood pressure (BP), then stop the infusion. Check pulse oximetry for O₂ percent saturation. Contact the ordering provider. Initiate emergency medications.



Patient Name: _____

Date of Birth: _____

 PHYO
 CMC85949-001NS Rev. 9/2021

**Tocilizumab (ACTEMRA)
 Infusion Therapy Plan**
ORDERS TO BE COMPLETED FOR EACH THERAPY
INTRA-PROCEDURE, CONTINUED
 Physician communication order

Dosing for Systemic JIA. Please enter the dose of tocilizumab in 'mg' to facilitate prior authorization requirements:

< 30 kg = 12 mg / kg / dose (in 50 mL NS)

> 30 kg 8 mg / kg / dose (in 100 mL NS)

adults ≥ 18 years old, initial dose = 4 mg / kg titrated up to 8 mg / kg (maximum dose = 800 mg).

Please select the appropriate order below. (First order is default in 50 mL for < 30 kg and second order is default in 100 mL for > 30 kg)

 tocilizumab in sodium chloride 0.9% 50 mL infusion **INTERVAL:** Every 2 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

INTRAVENOUS, at 50 mL / hour, ONCE, starting 0.5 hours after treatment start time, for 1 dose. Infuse over 60 minutes using a dedicated IV line. Do not administer IV push or IV bolus. Do not use if opaque particles or discoloration are visible. PROTECT FROM LIGHT.

Dose: _____

 tocilizumab in sodium chloride 0.9% 100 mL infusion **INTERVAL:** Every 2 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

INTRAVENOUS, at 100 mL / hour, ONCE, starting 0.5 hours after treatment start time, for 1 dose. Infuse over 60 minutes using a dedicated IV line. Do not administer IV push or IV bolus. Do not use if opaque particles or discoloration are visible. PROTECT FROM LIGHT.

Dose: _____

 Tocilizumab Every 4 Weeks for Polyarticular JIA
 Physician communication order

Routine, ONE TIME, CBC and liver panel to 2nd, 3rd, and 4th infusion, then every other month. Lipid panel before 3rd infusion, then every 6 months.

 Complete Blood Count With Differential **INTERVAL:** Every 2 weeks **DEFER UNTIL:** _____ **DURATION:** 3 treatments

Unit collect

Prior to 2nd, 3rd, and 4th infusion, then every other month.

 Complete Blood Count With Differential **INTERVAL:** Every 8 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

Unit collect

Every other month.

 Hepatic Function Panel **INTERVAL:** Every 2 weeks **DEFER UNTIL:** _____ **DURATION:** 3 treatments

Unit collect

Prior to 2nd, 3rd, and 4th infusion, then every other month.

 Hepatic Function Panel **INTERVAL:** Every 8 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

Unit collect

Every other month.

 Lipid Panel **INTERVAL:** Every 24 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

Unit collect

Prior to 3rd infusion, then every 6 months.

 Nursing communication

 Parameters to meet prior to administration: WBC ≥ 4 thousand / mm³ or ANC ≥ 1,500. Notify the ordering provider if aparameters are not met.

 Vital signs

 Monitor respiratory rate, pulse and blood pressure (BP) every 15 minutes during infusion and for a total of 30 minutes after patient completes infusion. If patient develops fever, chills, pruitus, urticaria, chest pain, shortness of breath low or high blood pressure (BP), then stop the infusion. Check pulse oximetry for O₂ percent saturation. Contact the ordering provider. Initiate emergency medications.

 tocilizumab in sodium chloride 0.9% 50 mL infusion **INTERVAL:** Every 4 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

INTRAVENOUS, at 50 mL / hour, ONCE, starting 0.5 hours after treatment start time. Infuse over 60 minutes using a dedicated IV line. Do not administer IV push or IV bolus. Do not use if opaque particles or discoloration are visible. PROTECT FROM LIGHT.

Dose: _____



Patient Name: _____

Date of Birth: _____

 PHYO
 CMC85949-001NS Rev. 9/2021

**Tocilizumab (ACTEMRA)
 Infusion Therapy Plan**
ORDERS TO BE COMPLETED FOR EACH THERAPY
INTRA-PROCEDURE, CONTINUED
 tocilizumab in sodium chloride 0.9% 100 mL infusion
INTERVAL: Every 4 weeks **DEFER UNTIL:** _____ **DURATION:** Until discontinued

INTRAVENOUS, at 100 mL / hour, ONCE, starting 0.5 hours after treatment start time, for 1 dose. Infuse over 60 minutes using a dedicated IV line. Do not administer IV push or IV bolus. Do not use if opaque particles or discoloration are visible. PROTECT FROM LIGHT.

Dose: _____

EMERGENCY MEDICATIONS
 Nursing communication
1. Hives or cutaneous reaction only – no other system involvement PATIENT IS HAVING A DRUG REACTION:

- a. Stop the infusion
- b. Give diphenhydramine as ordered
- c. Check vitals including blood pressure every 5 minutes until further orders from provider.
- d. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one
- e. Notify provider for further orders

2. Hives or cutaneous reaction plus one other system, i.e. abdominal cramping, vomiting, hypotension, altered mental status, respiratory distress, mouth / tongue swelling PATIENT IS HAVING ANAPHYLAXIS:

- a. Stop the infusion
- b. Call code – do not wait to give epinephrine
- c. Give epinephrine as ordered
- d. Notify provider
- e. Check vitals including blood pressure every 5 minutes until the code team arrives.
- f. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one.
- g. Give diphenhydramine once as needed for hives
- h. May repeat epinephrine every 5 minutes x 2 doses for persistent hypotension and respiratory distress with desaturation until code team arrives.
- i. May give albuterol as ordered for wheezing with oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation.

Hypotension is defined as follows:

- 1 month to 1 year – systolic blood pressure (SBP) less than 70
- 1 year to 11 years – systolic blood pressure (SBP) less than 70 + (2 x age in years)
- 11 years to 17 years – systolic blood pressure (SBP) less than 90
- OR any age – systolic blood pressure (SBP) drop more than 30% from baseline.
- Baseline systolic blood pressure (SBP) x 0.7 = value below defined as hypotension.

 EPINEPHrine Injection Orderable For Therapy Plan (AMPULE / EPI - PEN JR. / EPI - PEN) 0.01 mg / kg

0.01 mg / kg, INTRAMUSCULAR, EVERY 5 MINUTES PRN, for anaphylaxis and may be repeated for persistent hypotension and respiratory distress with desaturation until the code team arrives, for 3 doses

Use caution with PIV administration. This solution has a pH < 5, or a pH > 9, or an osmolality > 600 mOsm / L.

Dose: _____

 Cardio / Respiratory Monitoring Rationale for Monitoring: High risk patient (please specify risk)

- Clinically significant cardiac anomalies or dysrhythmias
- Recent acute life-threatening event
- Unexplained or acutely abnormal vital signs
- Artificial airway (stent, tracheostomy, oral airway)
- Acute, fluctuating or consistent oxygen requirements

 Monitor Parameters (select all that apply): Heart rate Oxygen saturation Respiratory rate

 Telemetry Required: Yes No

 diphenhydrAMINE injection

1 mg / kg, INTRAVENOUS, ONCE PRN, for hives or cutaneous reaction, for 1 dose. Maximum dose = 50 mg per dose, 300 mg per day.

Dose: _____



Patient Name: _____

Date of Birth: _____

PHYO
CMC85949-001NS Rev. 9/2021

**Tocilizumab (ACTEMRA)
Infusion Therapy Plan**

ORDERS TO BE COMPLETED FOR EACH THERAPY

EMERGENCY MEDICATIONS, CONTINUED

Albuterol for aerosol

0.25 mg / kg., INHALATION ONCE PRN, for wheezing, but oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation for 1 dose

Dose: _____

POST-PROCEDURE

Nursing communication

Flush PIV or IVAD with 20 mL 0.9% sodium chloride (250 mL bag) at the completion of the infusion.
Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD.
Discontinue PIV prior to discharge.

Sodium chloride 0.9% infusion

INTRAVENOUS, at 0 - 25 mL / hour ONCE, for 1 dose

Dose: _____

(circle one):
MD DO

Signature of Provider

Credentials

Date

Time

Printed Name of Provider